32. Kleiner DE, Brunt EM, Van Natta M. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41: 1313–21.
33. Vernon G; Baranova A; Younossi Z.M. The Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis in Adults. Alimentary Pharmacology & Therapeutics. 2011;34(3):274-285.
34. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008; 57: 1441–7.
35. Ruffillo G, Fassio E, Alvarez E. Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease. J Hepatol. 2011; 54: 160–3.
36. McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut. 2010; 59: 1265–9.
37. Raszeja-Wyszomirska J, Szymanik B, Lawniczak M. Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD). BMC Gastroenterol. 2010; 10: 67.
38. Fujii H, Enomoto M, Fukushima W, Tamori A, Sakaguchi H, Kawada N. Applicability of BARD score to Japanese patients with NAFLD. Gut. 2009; 58: 1566–7.
39. Loaeza-del-Castillo A, Paz-Pineda F, Oviedo-Cardenas E, Sanchez-Avila F, Vargas-Vorackova F. AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis. Ann Hepatol. 2008; 7: 350–7.
40. Fujii H, Enomoto M, Fukushima W. Noninvasive laboratory tests proposed for predicting cirrhosis in patients with chronic hepatitis C are also useful in patients with non-alcoholic steatohepatitis. J Gastroenterol. 2009; 44: 608–14.
41. Cales P, Oberti F, Michalak S. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology. 2005; 42: 1373–81.
42. Neuschwander-Tetri BA, Clark JM, Bass NM. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology. 2010; 52: 913–24.
43. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2010;34:2001-15
44. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009; 7: 1104–12.
45. Tahan V, Canbakan B, Balci H. Serum gamma-glutamyltranspeptidase distinguishes non-alcoholic fatty liver disease at high risk. Hepatogastroenterology. 2008; 55: 1433–8.
46. Qureshi K, Clements RH, Abrams GA. The utility of the 'NAFLD fibrosis score' in morbidly obese subjects with NAFLD. Obes Surg. 2008; 18: 264–70.
47. Wong VW, Wong GL, Chim AM. Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis. Am J Gastroenterol. 2008; 103: 1682–8.
48. Guha IN, Parkes J, Roderick P. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology. 2008; 47: 455–60.
49. Parkes J, Roderick P, Harris S. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut. 2010; 59: 1245–51.
50. Munteanu M, Ratziu V, Morra R, Messous D, Imbert-Bismut F, Poynard T. Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. J Gastrointestin Liver Dis. 2008; 17: 187–91.
51. Sakugawa H, Nakayoshi T, Kobashigawa K. Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol. 2005; 11: 255–9.
52. Santos VN, Leite-Mor MM, Kondo M. Serum laminin, type IV collagen and hyaluronan as fibrosis markers in non-alcoholic fatty liver disease. Braz J Med Biol Res. 2005; 38: 747–53.
53. Joy D, Thava VR, Scott BB. Diagnosis of fatty liver disease: is biopsy necessary? Eur J Gastroenterol Hepatol. 2003; 15: 539–43.
54. de Lédinghen V, Vergniol J, Foucher J, El-Hajbi F, Merrouche W, Rigalleau V. Feasibility of liver transient elastography with FibroScan using a new probe for obese patients. Liver Int. 2010; 30: 1043–8.
55. Yoneda M, Yoneda M, Fujita K. Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD). Gut. 2007; 56: 1330–1.
56. De Lédinghen V, Vergniol J. Transient elastography for the diagnosis of liver fibrosis. Expert Rev Med Devices. 2010; 7: 811–23.
57. Yin M, Talwalkar JA, Glaser KJ. Assessment of hepatic fibrosis with magnetic resonance elastography. ClinGastroenterol Hepatol 2007; 5: 1207–13. Wong VW, Vergniol J, Wong GL. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 2010; 51: 454–62.
58. Huwart L, Sempoux C, Vicaut E. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology. 2008; 135: 32–40.